Despite efforts to achieve a desirable weight, two-thirds of the population has an elevated body weight. Medications are useful in supporting weight loss, but produce adverse effects. This study compared the effects of amphetamine and modafinil on food intake and cardiovascular activity in healthy men and women. Participants (n = 11) completed 11 sessions. In random order, participants received...

Modafinil is a wakeness-promoting drug, which is effective in the treatment of narcolepsy; its effects on learning processes are however little studied. Thus, the present study was aimed at determining the effects of an acute modafinil injection on a serial reversal discrimination task performed in a T-maze in mice. Independent groups of mice varying by the level of pretest training (either 1 o...

Abstract Introduction Narcolepsy is a disorder of hypersomnolence affecting between 1:5000-1:10,000 individuals. Type 1 can be differentiated from 2 by the presence cataplexy. Visual hallucinations are reported in 50-80% T1 Narcoleptics and ~25% T2 Narcoleptics. This thought to REM-related phenomenon occurring at transitions sleep wakefulness. Auditory or paranoid delusions more rare. We report...

Excessive daytime sleepiness is a frequent and a highly disruptive symptom to the daily routine of children with Prader-Willi Syndrome (PWS) and their families. The objective of the study was to evaluate the efficacy of modafinil, a central stimulant, on excessive daytime sleepiness in children and adolescents with PWS. The efficacy of modafinil was evaluated in this open label pilot study comp...

Normally, mice sleep during the day and are active at night. In Huntington's disease mice (R6/2 line) this circadian pattern disintegrates progressively over the course of their illness. Cognitive decline and apathy in R6/2 mice can be improved with sleeping drugs, suggesting that sleep disruption contributes to their neurological decline. We wondered if wakefulness was equally important. Here,...

Modafinil (Provigil) is a medication used to promote wakefulness. Originally marketed in 1998, modafinil, a Schedule C-IV drug, was approved by the Food and Drug Administration (FDA) for the treatment of excessive sleepiness (ES) associated with narcolepsy. In 2003, the FDA approved modafinil for the treatment of ES associated with obstructive sleep apnea-hypopnea syndrome (only as an adjunct t...

13. Ripley B, Overeem S, Fujiki N, Nevsimalova S, Uchino M, Yesavage J, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001;57:2253-8. 14. Honda Y. Clinical features of narcolepsy: Japanese experiences. In: Honda Y, Juji T, editors. HLA in narcolepsy. Berlin: Springer-Verlag; 1988. p. 24-57. 15. US Modafinil in Narcolepsy Multicenter Study Group. ...

BACKGROUND AND PURPOSE Poststroke fatigue is common and reduces quality of life. Current evidence for intervention is limited, and this is the first placebo-controlled trial to investigate treatment of poststroke fatigue with the wakefulness promoting drug modafinil. METHODS The trial was randomized, double-blinded, and placebo-controlled. Patients were treated with 400-mg modafinil or placeb...

BACKGROUND Modafinil is employed for the treatment of narcolepsy and has also been, off-label, used to treat cognitive dysfunction in neuropsychiatric disorders. In a previous study, we have reported that single dose administration of modafinil in healthy young subjects enhances fluid reasoning and affects resting state activity in the Fronto Parietal Control (FPC) and Dorsal Attention (DAN) ne...

In the past few years, cognitive enhancing drugs (CEDs) have gained growing interest and the focus of investigations aimed at exploring their use to potentiate the cognitive performances of healthy individuals. Most of this exploratory CED-related research has been performed on young adults. However, CEDs may also help to maintain optimal brain functioning or compensate for subtle and or subcli...